What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)

Keskin, Muharrem; VARDAR, Rukiye

What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)

Rukiye VARDAR, (Department of Gastroenterology, Ege University School of Medicine, İzmir, Turkey)

Muharrem KESKİN (Department of Gastroenterology, Necmettin Erbakan University School of Medicine, Konya, Turkey)

Turkish Journal of Gastroenterology

0 0

Yıl: 2017 Cilt: 28 Sayı: 1 Sayfa Aralığı: 12 - 15 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)

Öz:

Empirical acid suppression tests that are performed with proton pump inhibitors (PPI) are used to detect both the presence of acid-related gastrointestinal symptoms and gastroesophageal reflux disease (GERD). In comparison to other diagnostic methods, it is non-invasive, easily applicable, and cost-effective in the diagnosis of GERD. In addition to typical reflux symptoms, it can also be used for diagnostic purposes in patients with non-cardiac chest pain (NCCP). If the symptom response is 50% and above when obtained using the PPI test in patients with NCCP, it can be considered as positive and the treatment should be continued sensitivity of the PPI test in patients with typical symptoms of GERD is 27%-89%, while its specificity is 35%-83%. Although there are differences related to the duration and dosage of the PPI test, a significant difference has not been found according to the type of PPI. When PPI test sensitivity and specificity were calculated by cumulatively evaluating the data regarding the PPI test in the literature, a sensitivity of 82.3% and specificity of 51.5% was obtained. It has been found that high doses of PPI were mostly used in studies, and the duration of the median test was 14 days. As a result, the sensitivity of PPI trial test is good, but the specificity is low in the diagnosis of GERD in patients with typical reflux symptoms

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140: 518-27. [CrossRef]
2. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000.
3. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115: 42-9. [CrossRef]
4. Schindlbeck NE, Klauser AG, Voderholzer WA, Muller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995; 155: 1808-12. [CrossRef]
5. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. Oneweek omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33: 15-20. [CrossRef]
6. Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999; 159: 2161-8. [CrossRef]
7. Bate CM, Riley SA, Chapman RW, Durnin AT, Taylor MD. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 59-66. [CrossRef]
8. Juul-Hansen P, Rydning A, Jacobsen CD, Hansen T. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand J Gastroenterol 2001; 36: 806-10. [CrossRef]
9. Pandak WM, Arezo S, Everett S, et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J Clin Gastroenterol 2002; 35: 307-14. [CrossRef]
10. Xia HH, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 2003; 17: 369-77. [CrossRef]
11. Bautista J, Fullerton H, Briseno M, Cui H, Fass R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, doubleblind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2004; 19: 1123-30. [CrossRef]
12. Dickman R, Emmons S, Cui H, et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2005; 22: 547-55. [CrossRef]
13. des Varannes SB, Sacher-Huvelin S, Vavasseur F, et al. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. World J Gastroenterol 2006; 12: 2569-73. [CrossRef]
14. Ho KY, Gwee KA, Khor CJ, Selamat DS, Wai CT, Yeoh KG. Empirical treatment for the management of patients presenting with uninvestigated reflux symptoms: a prospective study in an Asian primary care population. Aliment Pharmacol Ther 2005; 21: 1313-20. [CrossRef]
15. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol 2001; 96: 979-83. [CrossRef]
16. Ofman JJ, Gralnek IM, Udani J, Fennerty MB, Fass R. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999; 107: 219-27. [CrossRef]
17. Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastrooesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 261-73. [CrossRef]
18. Squillace SJ, Young MF, Sanowski RA. Single Dose Omeprazole as a Test for Noncardiac Chest Pain. Gastroenterology 1993; 104: A197-A.
19. Maev IV, Iurenev GL, Burkov SG, V'Iuchnova ES. Rabeprazole test and comparison of the effectiveness of course treatment with rabeprazole in patients with gastroesophageal reflux disease and non-coronary chest pain. Klin Med (Mosk) 2007; 85: 45-51.
20. Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10: 1360-6. [CrossRef]
21. Juul-Hansen P, Rydning A. Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice? Scand J Gastroenterol 2003; 38: 1200-3. [CrossRef]
22. Johnsson F, Hatlebakk JG, Klintenberg AC, et al. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. Scand J Gastroenterol 2003; 38: 354-9. [CrossRef]
23. Pace F, Pace M. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 2010; 4: 423-7. [CrossRef]
24. Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60: 1473-8. [CrossRef]
25. Kim JH, Sinn DH, Son HJ, Kim JJ, Rhee JC, Rhee PL. Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. J Gastroenterol Hepatol 2009; 24: 1504-9. [CrossRef]
26. Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a metaanalysis. Arch Intern Med 2005; 165: 1222-8. [CrossRef]
27. Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010; 59: 714-21. [CrossRef]
28. Cho YK, Choi MG, Lim CH, et al. Diagnostic value of the PPİ test for detection of GERD in Korean patients and factors associated with PPİ responsiveness. Scand J Gastroenterol 2010; 45: 533-9. [CrossRef]
29. Aanen MC, Weusten BL, Numans ME, de Wit NJ, Baron A, Smout AJ. Diagnostic value of the proton pump inhibitor test for gastrooesophageal reflux disease in primary care. Aliment Pharmacol Ther 2006; 24: 1377-84. [CrossRef]
30. Dekel R, Martinez-Hawthorne SD, Guillen RJ, Fass R. Evaluation of symptom index in identifying gastroesophageal reflux disease-related noncardiac chest pain. J Clin Gastroenterol 2004; 38: 24-9. [CrossRef]
31. Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 2000; 14: 389-96. [CrossRef]

APA	VARDAR R, Keskin M (2017). What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). , 12 - 15.
Chicago	VARDAR Rukiye,Keskin Muharrem What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). (2017): 12 - 15.
MLA	VARDAR Rukiye,Keskin Muharrem What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). , 2017, ss.12 - 15.
AMA	VARDAR R,Keskin M What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). . 2017; 12 - 15.
Vancouver	VARDAR R,Keskin M What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). . 2017; 12 - 15.
IEEE	VARDAR R,Keskin M "What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)." , ss.12 - 15, 2017.
ISNAD	VARDAR, Rukiye - Keskin, Muharrem. "What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)". (2017), 12-15.

APA	VARDAR R, Keskin M (2017). What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). Turkish Journal of Gastroenterology, 28(1), 12 - 15.
Chicago	VARDAR Rukiye,Keskin Muharrem What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). Turkish Journal of Gastroenterology 28, no.1 (2017): 12 - 15.
MLA	VARDAR Rukiye,Keskin Muharrem What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). Turkish Journal of Gastroenterology, vol.28, no.1, 2017, ss.12 - 15.
AMA	VARDAR R,Keskin M What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). Turkish Journal of Gastroenterology. 2017; 28(1): 12 - 15.
Vancouver	VARDAR R,Keskin M What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage). Turkish Journal of Gastroenterology. 2017; 28(1): 12 - 15.
IEEE	VARDAR R,Keskin M "What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)." Turkish Journal of Gastroenterology, 28, ss.12 - 15, 2017.
ISNAD	VARDAR, Rukiye - Keskin, Muharrem. "What is the place of empirical proton pump inhibitor testing in the diagnosis of gastroesophageal reflux disease? (Description, duration, and dosage)". Turkish Journal of Gastroenterology 28/1 (2017), 12-15.